258 related articles for article (PubMed ID: 19527709)
1. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice.
Mor A; Kloog Y; Keren G; George J
Eur J Pharmacol; 2009 Aug; 616(1-3):301-5. PubMed ID: 19527709
[TBL] [Abstract][Full Text] [Related]
2. N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells.
Mor A; Keren G; Kloog Y; George J
Eur J Immunol; 2008 Jun; 38(6):1493-502. PubMed ID: 18461565
[TBL] [Abstract][Full Text] [Related]
3. Ras inhibition attenuates pancreatic cell death and experimental type 1 diabetes: possible role of regulatory T cells.
Aizman E; Mor A; George J; Kloog Y
Eur J Pharmacol; 2010 Sep; 643(1):139-44. PubMed ID: 20599916
[TBL] [Abstract][Full Text] [Related]
4. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells.
Van YH; Lee WH; Ortiz S; Lee MH; Qin HJ; Liu CP
Diabetes; 2009 Jan; 58(1):146-55. PubMed ID: 18984738
[TBL] [Abstract][Full Text] [Related]
6. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats.
da Silva Morais A; Saliez A; Leclercq I; Horsmans Y; Stärkel P
Clin Sci (Lond); 2008 Jan; 114(1):73-83. PubMed ID: 17678500
[TBL] [Abstract][Full Text] [Related]
8. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
[TBL] [Abstract][Full Text] [Related]
9. Critical role of IFN-gamma in CFA-mediated protection of NOD mice from diabetes development.
Mori Y; Kodaka T; Kato T; Kanagawa EM; Kanagawa O
Int Immunol; 2009 Nov; 21(11):1291-9. PubMed ID: 19778991
[TBL] [Abstract][Full Text] [Related]
10. The Ras antagonist farnesylthiosalicylic acid ameliorates experimental myocarditis in the rat.
Pando R; Barshack I; Raz A; Luboshits G; Haklai R; Maysel-Auslender S; Kloog Y; Keren G; George J
Cardiovasc Pathol; 2010; 19(2):94-101. PubMed ID: 19144546
[TBL] [Abstract][Full Text] [Related]
11. Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR-mediated activation of p21(ras).
Rapoport MJ; Weiss L; Mor A; Bistritzer T; Ramot Y; Slavin S
J Immunol; 1996 Nov; 157(10):4721-5. PubMed ID: 8906854
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor.
George J; Sack J; Barshack I; Keren P; Goldberg I; Haklai R; Elad-Sfadia G; Kloog Y; Keren G
Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):363-8. PubMed ID: 14670932
[TBL] [Abstract][Full Text] [Related]
13. A novel mechanism of regulatory T cell-mediated down-regulation of autoimmunity.
Qin HY; Mukherjee R; Lee-Chan E; Ewen C; Bleackley RC; Singh B
Int Immunol; 2006 Jul; 18(7):1001-15. PubMed ID: 16675487
[TBL] [Abstract][Full Text] [Related]
14. Suppression of type 1 diabetes in NOD mice by bifunctional peptide inhibitor: modulation of the immunological synapse formation.
Murray JS; Oney S; Page JE; Kratochvil-Stava A; Hu Y; Makagiansar IT; Brown JC; Kobayashi N; Siahaan TJ
Chem Biol Drug Des; 2007 Sep; 70(3):227-36. PubMed ID: 17718717
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of regulatory T-cell induction by antigen-IgG-transduced splenocytes.
Wang R; Song L; Han G; Wang J; Chen G; Xu R; Yu M; Qian J; Shen B; Li Y
Scand J Immunol; 2007 Nov; 66(5):515-22. PubMed ID: 17883389
[TBL] [Abstract][Full Text] [Related]
16. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
17. Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency.
Xue S; Wasserfall CH; Parker M; Brusko TM; McGrail S; McGrail K; Moore M; Campbell-Thompson M; Schatz DA; Atkinson MA; Haller MJ
Ann N Y Acad Sci; 2008 Dec; 1150():152-6. PubMed ID: 19120286
[TBL] [Abstract][Full Text] [Related]
18. GAD-IgG-inducing CD4+Foxp3+Treg cells suppressing diabetes are involved in the increasing ratio of CD80+:CD86+ CELLS in NOD mice.
Wang R; Han G; Wang J; Song L; Chen G; Xu R; Zhang C; Yu M; Qian J; Shen B; Li Y
Arch Med Res; 2008 Apr; 39(3):299-305. PubMed ID: 18279702
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice.
Kolar P; Knieke K; Hegel JK; Quandt D; Burmester GR; Hoff H; Brunner-Weinzierl MC
Arthritis Rheum; 2009 Jan; 60(1):123-32. PubMed ID: 19116935
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive therapy exacerbates autoimmunity in NOD mice and diminishes the protective activity of regulatory T cells.
Kaminitz A; Mizrahi K; Yaniv I; Stein J; Askenasy N
J Autoimmun; 2010 Sep; 35(2):145-52. PubMed ID: 20638242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
